Phase Ib Pilot Study of Itacitinib With Alemtuzumab in Patients With T-Cell Prolymphocytic Leukemia (T-PLL)
Latest Information Update: 15 Oct 2024
At a glance
- Drugs Alemtuzumab (Primary) ; Itacitinib (Primary)
- Indications T-cell prolymphocytic leukaemia
- Focus Adverse reactions
Most Recent Events
- 27 Sep 2024 Status changed from active, no longer recruiting to completed.
- 08 May 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2026.
- 30 May 2023 Status changed from recruiting to active, no longer recruiting.